Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of long-acting reversible contraception on depression and related outcomes
PACTR201706001651380Recruiting
- Sponsor
- South African Medical Research Council
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of medroxyprogesterone acetate, avatrombopag, copper intrauterine device and norethisterone enanthate in major depressive disorder (MDD), sexual dysfunction and Menstrual cycle and uterine bleeding disorders (AUB) (4 arms), sponsored by South African Medical Research Council. Primary endpoint: Depression. Started May 2016; status: recruiting.
02
Drugs
medroxyprogesterone acetateavatrombopagcopper intrauterine devicenorethisterone enanthate
03
Conditions
major depressive disorder (MDD)sexual dysfunctionMenstrual cycle and uterine bleeding disorders (AUB)
Beyond the preview
Go deeper on PACTR201706001651380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201706001651380.